Skip to main content
snıff

Golden Retriever

3,523 Golden Retrievers in the atlas. Every number on this page has a source.

3,523 Golden Retrievers in the Sniff atlas. Population-genetic snapshot, top five Mendelian variants with source-graded carrier frequencies, longevity outliers from the Golden Retriever Lifetime Study, and nutrition guidance tied to the genetic findings above.

See in the atlas → From CanVAS GRLS cohort The Heroes →
What the atlas says about Golden Retriever

In the atlas, the Golden Retriever clusters consistently as Golden Retriever (100% of the 3523 dogs here). At the trait loci, the FGF4_retrogene_CFA18 variant is near-fixed at 100% vs 77% atlas-wide.

High breed predictability score (0.93), individual dogs of this breed reliably cluster together genetically. Well-sampled in CanVAS: 3,523 dogs.

Closest genetic neighbors in the atlas: Labrador Or Golden Retriever, Flat Coated Retriever, Chesapeake Bay Retriever, Dalmatian, and Giant Schnauzer.

Median lifespan is 13.15 years, about 1.5 years longer than a typical dog of 29.5 kg, an unusually positive longevity for this size.

Genetic dimensions · CanVAS atlas

What the genome says about Golden Retriever

Computed from the 18,477 research dogs in the Atlas.

Dogs in the Atlas
3,523Founders
3,197 from GRLS, 247 from Hayward2016, 57 from Shannon
Genetic diversity
0.28Moderate
Mean heterozygosity across the breed. Ranks 28th most genetically tight of 107 ranked breeds.
Cluster structure
Single tight cluster
Intra-breed RMS distance: 35.80
Nearest genetic relatives
  1. Labrador Or Golden Retrieverartifact4.51
  2. Flat Coated Retriever4.82
  3. Chesapeake Bay Retriever5.53
  4. Dalmatian6.37
  5. Giant Schnauzer7.92
Top-10 PC corrected Euclidean. Lower = closer.
Rows tagged artifact are CanVAS mixed-label entries the upstream pipeline could not unambiguously assign to one parent breed. Displayed honestly rather than hidden.
How long they live
13.2years (atlas median)
Breed-club estimate: 10 to 12 years (Morris Animal Foundation).
The atlas median is computed from the GRLS cohort, which enrolled in 2012 and is being followed to natural mortality. The figure is partial and will shift downward as the remaining dogs age. The breed-club estimate is closer to the lifespan an owner should expect today.
Trait genetics
Allele frequencies at named morphology loci

Frequency of the alternate allele in this breed at each locus's representative SNP.

Body size
IGF152%
HMGA285%
SMAD289%
LCORL98%
STC292%
ADAMTS1728%
Leg length
FGF4·CFA18100%
FGF4·CFA1299%
Coat
RSPO255%
FGF562%
KRT71100%
MC1R39%
Ear set
MSRB3100%
Skull shape
BMP354%
SMOC283%
What you see when you look at a Golden Retriever

What does the genome say about how a Golden Retriever looks?

Golden Retrievers look the way they do because of a small set of fixed and near-fixed morphology genes that, taken together, define the visible breed. Each translation below pairs the gene with the trait an owner actually sees, the breed's allele frequency at that locus, and a one-clause causal phrase.

Size and build

IGF1 sits at 52% for the small-body allele. IGF1 is the gene that sets dog body size from Chihuahua to Great Dane. Intermediate frequencies typically keep a breed in the mid-sized range rather than tipping toward the larger working forms.

HMGA2 is near-fixed at 85%, reinforcing the breed's size signal through a second locus on chromosome 10.

SMAD2 is near-fixed at 89%, a chromosome-7 height locus differentiating small from giant breeds.

LCORL is near-fixed at 98%, the NCAPG/LCORL height locus that is one of the strongest single contributors to canine body size.

STC2 is near-fixed at 92%, modulating growth-axis signaling toward the breed's body-size set point.

ADAMTS17 is at 28%, the lower-frequency allele in this breed.

Leg length

The FGF4 retrogene on chromosome 18 is near-fixed in this breed at 100%. This is the leg-length variant. The breed is fully committed to the long-legged form rather than the short-legged Corgi-and-Dachshund body plan.

The FGF4 retrogene on chromosome 12 is near-fixed at 99%, the chondrodystrophic variant associated with intervertebral disc disease risk in breeds that carry it.

Coat type, length, and color

RSPO2 is at 55% in Goldens. Furnishings (the eyebrow-and-mustache pattern seen in Schnauzers and Wheaten Terriers) vary at the population level, though most Goldens do not display visible furnishings.

FGF5 is at 62% for the long-coat allele. Despite this intermediate frequency, Goldens consistently present with a clearly long coat, suggesting other loci or the specific allele definition contribute to the visible phenotype.

KRT71 is fixed at 100% for the curl variant in Goldens. Despite this, visible coat curl varies from straight to wavy across individuals, suggesting modifiers or environmental factors influence expression. The flat coat some Goldens carry is not due to variation at this locus.

MC1R sits at 39% at the representative SNP in Goldens. The visible phenotype is unambiguous: Goldens are gold-to-red because the e/e homozygous genotype at MC1R blocks black and brown pigment expression. Breeder selection for the gold-to-red phenotype keeps the e/e state effectively universal in the breed standard. The 39% substrate frequency at this representative SNP depends on the array's polarity at this specific SNP and does not contradict the unambiguous phenotype.

Ears

MSRB3 is at 100% for the drop-ear allele, the genetic basis of the breed's signature dropped ear set.

Skull shape

BMP3 sits at 54%, contributing to the breed's moderate, mesaticephalic head shape rather than the extreme brachycephalic form.

SMOC2 sits at 83%, contributing to the breed's moderate head shape.

Mendelian-disease genetics

What genetic diseases do Golden Retrievers carry?

From a panel of 250 Mendelian-disease variants screened in 1,054,293 dogs (Donner et al. 2023), Golden Retrievers carry 33 of them at observable frequency. Carrier frequency is not clinical risk. Most recessive variants require two copies for disease expression; many dominant variants show incomplete penetrance. Read this as a population fingerprint of what's in the gene pool, not a per-dog prediction.

Ichthyosis (Discovered in the Golden Retriever)
Autosomal recessive
high 27.5%
n = 12,881 dogs · 1 variant tested · OMIA:001588-9615 · omia.org →
Cystinuria Type I-B (SLC7A9 p.A217T)
Autosomal recessive (Incomplete penetrance)
high 23.7%
n = 12,881 dogs · 2 variants tested · OMIA:001880-9615 · omia.org →
Progressive Retinal Atrophy (Discovered in the Golden Retriever; GR_PRA2)
Autosomal recessive
low 2.8%
n = 12,881 dogs · 1 variant tested · OMIA:001984-9615 · omia.org →
Progressive Rod-Cone Degeneration (prcd-PRA)
Autosomal recessive
low 2.7%
n = 12,860 dogs · 1 variant tested · OMIA:001298-9615 · omia.org →
Progressive Retinal Atrophy (Discovered in the Golden Retriever; GR_PRA1)
Autosomal recessive
low 1.6%
n = 12,860 dogs · 1 variant tested · OMIA:001572-9615 · omia.org →
Congenital Myasthenic Syndrome (Discovered in the Heideterrier; CHRNE-related; CMS)
Autosomal recessive
low 0.23%
n = 12,880 dogs · 2 variants tested · OMIA:000685-9615 · omia.org →
Chondrodystrophy and Intervertebral Disc Disease Risk (CDDY)
Autosomal dominant
low 0.18%
n = 12,842 dogs · 1 variant tested · OMIA:000157-9615 · omia.org →
Degenerative Myelopathy (DM)
Autosomal recessive (Incomplete penetrance)
low 0.17%
n = 12,881 dogs · 1 variant tested · OMIA:000263-9615 · omia.org →
Acral Mutilation Syndrome (AMS)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 1 variant tested · OMIA:001514-9615 · omia.org →
Congenital Myasthenic Syndrome (Discovered in the Labrador Retriever)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 2 variants tested · OMIA:001928-9615 · omia.org →
Exercise-Induced Collapse (EIC)
Autosomal recessive (Incomplete penetrance)
low <0.1%
n = 12,879 dogs · 1 variant tested · OMIA:001466-9615 · omia.org →
Von Willebrand's Disease, Type 1 (vWD 1)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 1 variant tested · OMIA:001057-9615 · omia.org →
Progressive Retinal Atrophy (Discovered in the Swedish Vallhund; MERTK-related)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 1 variant tested · OMIA:001932-9615 · omia.org →
MDR1 (Multidrug Resistance 1) Medication Sensitivity
Autosomal dominant
low <0.1%
n = 12,880 dogs · 1 variant tested · OMIA:001402-9615 · omia.org →
Early-Onset Progressive Polyneuropathy (Discovered in the Greyhound)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 2 variants tested · OMIA:002120-9615 · omia.org →
Collie Eye Anomaly (CEA)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 1 variant tested · OMIA:000218-9615 · omia.org →
Stargardt Disease (Discovered in the Labrador Retriever)
Autosomal recessive
low <0.1%
n = 12,881 dogs · 1 variant tested · OMIA:002179-9615 · omia.org →
Factor VII Deficiency
Autosomal recessive
low <0.1%
n = 12,881 dogs · 1 variant tested · OMIA:000361-9615 · omia.org →
Cone-Rod Dystrophy (cord1-PRA/crd4)
Autosomal recessive (Incomplete penetrance)
low <0.1%
n = 12,853 dogs · 1 variant tested · OMIA:001432-9615 · omia.org →
Rod-Cone Dysplasia 1a (Discovered in the Sloughi; rcd1a)
Autosomal recessive
low <0.1%
n = 12,875 dogs · 1 variant tested · OMIA:001669-9615 · omia.org →
Plus 13 more at lower frequency. Full table available via the API when shipped.
Source: Donner J et al. 2023. Frequencies of inherited disease variants in dogs. PLOS Genetics 19(2):e1010651 · Evidence: Limited (DTC ascertainment, tag-SNP proxy) · Confounding MEDIUM · License CC-BY-4.0 · Phene IDs from OMIA (Sydney School of Veterinary Science, The University of Sydney; DOI 10.25910/2AMR-PV70).
Sample size in this breed: 12,881 dogs from the Donner 2023 cohort.

Which Mendelian variants matter most for Golden Retrievers?

The Mendelian-disease table above lists 195 variants screened in 12,881 Goldens (Donner 2023). Five matter most by carrier frequency, and the first two matter most by impact.

Ichthyosis (PNPLA1)

Ichthyosis in Goldens is a recessive skin condition caused by a deletion in PNPLA1. Affected dogs have flaky, scaly skin that gets worse with age. It is cosmetic and manageable, not life-threatening. About 27.5% of Goldens in the Donner cohort carry the variant (n=12,881). More than one in four. It is the most common Mendelian variant in the breed and the single most consequential number on this page.

Testing is widely available. The PennGen Laboratory and most commercial DNA labs cover PNPLA1. The Golden Retriever Club of America’s health committee recommends testing breeding stock to avoid carrier-by-carrier pairings. For pet dogs the test is informative but not clinically required.

Cystinuria Type I-B (SLC7A9 p.A217T)

Cystinuria Type I-B in Goldens is the autosomal-recessive-with-incomplete-penetrance form of cystinuria. The SLC7A9 variant causes excess urinary cystine excretion and predisposes to bladder stones. 23.7% of Goldens in the Donner cohort carry the variant.

Not every dog with two copies forms stones, which is why the inheritance is described with incomplete penetrance. Testing is available. Affected dogs are managed with diet (low-protein, alkalinizing) and monitoring. Owners of carrier dogs should mention the result to their vet at routine visits even if their dog never shows symptoms.

Retinal atrophy variants (TTC8, PRCD, SLC4A3)

Three progressive retinal atrophy variants run at observable frequency in Goldens. The TTC8-related form is at 2.8% carrier frequency, PRCD (progressive rod-cone degeneration) at 2.7%, and the SLC4A3-related form at 1.6%. All three are recessive: a dog needs two copies to be affected, and affected dogs are well below 1% of the breed.

Affected dogs lose night vision first, then day vision, typically beginning in middle age. The OFA Companion Animal Eye Registry maintains the screening protocol. The GRCA recommends annual eye exams for breeding stock.

How should I test my Golden Retriever?

A breed-specific panel from a CLIA-accredited lab is the high-yield path. The minimum useful set for Goldens is PNPLA1 (ichthyosis), SLC7A9 (cystinuria), PRCD, TTC8 (GR-PRA2), SLC4A3 (GR-PRA1), and MDR1. Most commercial panels also include ten to fifteen additional Golden-relevant variants in a single draw. For breeding stock the GRCA’s recommended panel is the current standard. For pet dogs the same panel is informative but not clinically required.

What should I feed a Golden Retriever?

Feeding a Golden well means feeding around the breed’s known genetic vulnerabilities, which are the ones the section above documents. Three of those vulnerabilities shape the food decision: a documented diet-associated cardiac signal, intermediate-frequency hip dysplasia heritability, and the 27.5% ichthyosis carrier frequency affecting skin and coat.

Grain-free, pulse-heavy diets carry a real risk for this breed. The FDA’s 2018 advisory and Adin et al. 2019 (JVIM) flagged taurine-related dilated cardiomyopathy in Goldens fed certain grain-free formulations. Goldens were the most-reported breed in the FDA dataset, with 121 of 1,382 canine cases (FDA, 2022). The atlas does not yet carry a Mendelian-genetic DCM variant in Goldens; the signal is dietary and likely involves pulse-heavy formulations rather than the absence of grains per se. The conservative default for the breed is a grain-inclusive, taurine-supplemented adult formulation from a manufacturer that runs feeding trials. Read more in the grain-free DCM guide.

Joint care matters because the breed’s hip dysplasia rate is high. The Orthopedic Foundation for Animals reports 19.8% hip dysplasia prevalence across 199,402 Golden evaluations (OFA hip statistics), with elbow dysplasia at 11.4%. These conditions have a heritable component, and severity is directly influenced by two things owners control: growth rate during puppyhood and body weight throughout life. A large-breed puppy formulation with controlled calcium (0.8 to 1.6% on a dry-matter basis per NRC 2006) and a calcium-to-phosphorus ratio between 1.1:1 and 2:1 is the right starting point. Adult-life weight management is the other half. The 2023 APOP survey found 63% of US dogs were overweight or obese, a condition that worsens dysplasia symptoms measurably.

Skin and coat for Goldens is a downstream consequence of the 27.5% ichthyosis carrier frequency described above. Diets rich in omega-3 fatty acids from marine sources such as fish oil reduce the cosmetic burden of mild ichthyosis and support coat quality in unaffected dogs. Adequate zinc and biotin help here too. The Sniff Score corpus filters can identify products that hit these criteria in the price band the owner is shopping.

What we don’t know

The mechanism behind diet-associated DCM is still unsettled. We do not know if the issue is the presence of pulse ingredients, the absence of grains, a taurine deficiency in certain formulations, or a combination of factors. The breed-specific susceptibility is real enough that grain-inclusive diets remain the conservative default. We do not know precisely why Goldens appear in the FDA reports at a higher rate than other breeds.

Cancer is the breed’s defining health problem. Roughly 60% of Goldens die of cancer (Morris Animal Foundation GRLS), one of the highest rates of any breed. Hemangiosarcoma and lymphoma together account for more than half of GRLS cancer diagnoses. The Golden Retriever Lifetime Study has spent fourteen years looking for environmental, dietary, and genetic predictors. The honest summary is that the published analyses have come back mostly null. We do not yet have proven dietary prevention strategies for cancer in this breed. The data the GRLS cohort is producing will sharpen that picture in the next few years.

Frequently asked questions about Golden Retrievers

Are Golden Retrievers more likely to get cancer than other breeds? Yes. Roughly 60% of Goldens die of cancer (Morris Animal Foundation), one of the highest rates of any breed. The four dominant cancers are hemangiosarcoma, lymphoma, osteosarcoma, and mast cell tumors. The published environmental and dietary analyses from the GRLS cohort have come back mostly null so far, which means proven prevention strategies are not yet available.

What is the most common genetic disease in Golden Retrievers? Ichthyosis, caused by a variant in PNPLA1. 27.5% of Goldens carry one copy and roughly 7.6% are affected (Donner 2023, n=12,881). It is a cosmetic skin condition, not life-threatening, and is the most common Mendelian variant in the breed.

Should I do a DNA test on my Golden Retriever? For breeding stock, yes. The GRCA recommends a panel covering ichthyosis, cystinuria, the three retinal atrophy variants, and MDR1 at minimum. For pet dogs, testing is informative but not clinically required. The highest-yield single tests are PNPLA1 (ichthyosis) and SLC7A9 (cystinuria).

How long do Golden Retrievers live? The breed-club estimate is 10 to 12 years (Morris Animal Foundation). The atlas-derived figure from the GRLS cohort is 13.15 years, but that median will shift downward as the cohort completes its lifespan. Both numbers belong on this page. The breed-club figure is closer to what an owner should expect today.

Are field-line and show-line Goldens genetically different? The Sniff atlas substrate currently classifies Goldens as a single genetic cluster with an intra-breed RMS distance of 35.8. Show-line and field-line Goldens may differ at finer resolution than the substrate currently captures. Higher-resolution data arriving later this year will resolve this question one way or the other.

Is grain-free food safe for Golden Retrievers? The FDA’s 2018 advisory and Adin et al. 2019 (JVIM) flag taurine-related DCM in Goldens fed certain grain-free, pulse-heavy formulations. Grain-inclusive, taurine-supplemented diets from manufacturers that run feeding trials are the conservative default for the breed. See the DCM guide for the longer treatment.

When should I switch my Golden to a senior food? Around age 7 to 8. The goal is a food with high-quality protein to counter age-related muscle loss. NRC 2006 recommends a minimum of 2.5 grams of protein per kilogram of body weight per day for healthy senior dogs. Strong muscles support aging joints. Omega-3 fatty acids from marine sources support joint comfort and skin condition in dogs whose ichthyosis status is unknown.

What is the GRLS and why does it matter for Golden Retrievers? The Golden Retriever Lifetime Study is a fourteen-year longitudinal study of 3,044 Goldens run by the Morris Animal Foundation. It is the most detailed map of canine health ever assembled in any breed. Sniff is not affiliated with the Morris Animal Foundation. The cohort’s data is what makes the lifespan median, the cancer rate, and the Distinguished Oldies count on this page possible.

The oldest of them

What protected the golden retrievers who outran the odds.

Goldens in the GRLS cohort who reached age 12 or older without a malignant cancer diagnosis. In a breed where roughly 60% die of cancer and breed-club median lifespan is 10 to 12 years, reaching 12 without cancer is extraordinary. They carry the Distinguished Oldies badge in the atlas. Understanding what protected them is the most valuable single question the Golden Retriever literature can answer.

196 Distinguished Oldies in the atlas Browse the Heroes →
The data behind this page

Where every number on this page came from.

This page draws on three primary data sources. Carrier frequencies for the Mendelian section come from Donner et al. 2023 (CC-BY-4.0). We grade these data at evidence Limited because the cohort is a direct-to-consumer ascertainment, which biases toward owners who chose to test their dogs. The panel also uses tag-SNP proxies for some variants rather than direct causal-variant assays. Limited is a study-design grade, not a quality grade: the Donner cohort is the largest open canine-genotype dataset in existence and we are grateful for it. We rate the confounding MEDIUM.

Population-genetic dimensions (heterozygosity, intra-breed PCA distance, nearest neighbors, trait-locus frequencies) come from CanVAS (Brundage 2026), harmonized through the Sniff Atlas. The exact release date and verification commit are pinned at the bottom of the page so a researcher can trace a number back to a specific snapshot. The disease-gene-variant graph comes from OMIA (Online Mendelian Inheritance in Animals; Nicholas, Tammen, and the Sydney Informatics Hub at the Sydney School of Veterinary Science, The University of Sydney; retrieved April 2026, DOI 10.25910/2AMR-PV70).

Longitudinal data on the 196 Distinguished Oldies above comes from the Golden Retriever Lifetime Study (Guy and Page 2022, doi:10.1371/journal.pone.0269425). Sniff is not affiliated with the Morris Animal Foundation. We are grateful for their work and for every family and every dog that made this study real.

What this page does not yet have. Inheritance modes and per-disease penetrance evidence from Donner 2023 are now in the structured data for every variant the panel covers. Mondo, OMIM, Ensembl, and HGNC cross-references on gene pages remain pending — they arrive in December 2026 alongside the imputed 9.67M-variant CanVAS dataset via the OMIA SQL dump absorption. Until then, gene IDs carry NCBI Gene and OMIA phene URLs only; the wider human-homolog and disease-ontology cross-reference set fills in with that release.

How to cite this page. The computed dimensions on this page are derived from the open Sniff Atlas v1.0.1 (Gehring 2026, doi:10.5281/zenodo.20566358, CC-BY 4.0). Full citation formats including BibTeX, RIS, and CITATION.cff at sniff.world/cite.

Add your golden retriever to the atlas

We have 3,523 golden retrievers. We do not have yours.

Field-line Goldens are underrepresented relative to show lines. Goldens older than 12 without a cancer diagnosis are scientifically among the most valuable dogs in the breed and we always need more of them. European imports are underrepresented relative to North American lines. If your golden retriever fits any of these gaps, adding them does measurable scientific work.

Add your golden retriever now as a Charted star
Want to wait for DNA uploads?

Leave your email and we'll let you know the moment DNA uploads open for Golden Retrievers.

References
  1. Donner J, Anderson H, Davison S, et al. (2023). Frequency and distribution of 152 genetic disease variants in over 1,000,000 mixed-breed and purebred dogs. PLOS Genetics 19(2):e1010651. doi:10.1371/journal.pgen.1010651
  2. Brundage J, et al. (2026). CanVAS: a harmonized canine variant atlas. bioRxiv. doi:10.64898/2026.04.13.718238
  3. Nicholas, F.W., Tammen, I., & Sydney Informatics Hub. (2026). Online Mendelian Inheritance in Animals (OMIA) [dataset]. The University of Sydney. https://omia.org. doi:10.25910/2AMR-PV70 (retrieved April 2026).
  4. Guy MK, Page RL, et al. (2022). The Golden Retriever Lifetime Study: establishing an observational cohort study. PLOS ONE 17(6):e0269425. doi:10.1371/journal.pone.0269425
  5. Adin D, DeFrancesco TC, Keene B, et al. (2019). Echocardiographic phenotype of canine dilated cardiomyopathy differs based on diet type. J Vet Intern Med 33(2):541-550. doi:10.1111/jvim.15402
  6. US Food and Drug Administration (2022). Questions & Answers: FDA's work on potential causes of non-hereditary DCM in dogs. https://www.fda.gov/animal-veterinary/animal-health-literacy/questions-answers-fdas-work-potential-causes-non-hereditary-dcm-dogs
  7. Orthopedic Foundation for Animals (OFA). Golden Retriever hip dysplasia statistics. https://www.ofa.org/diseases/hip-dysplasia/
  8. Tindle AN, Page RL, et al. (2024). Environmental exposures and cancer risk in the Golden Retriever Lifetime Study cohort. https://www.morrisanimalfoundation.org/golden-retriever-lifetime-study
Last updated
Sources: CanVAS (Brundage 2026) · Donner 2023 · OMIA · GRLS (Guy and Page 2022)